常染色体显性多囊肾病
多囊肾病
小RNA
肾
囊肿
包装D1
生物
癌症研究
肾脏疾病
发病机制
RNA干扰
病理
医学
内分泌学
基因
免疫学
遗传学
核糖核酸
作者
Ronak Lakhia,Sachin Hajarnis,Darren R. Williams,Karam Aboudehen,Matanel Yheskel,Chao Xing,Mark E. Hatley,Vicente E. Torres,Darren P. Wallace,Vishal Patel
出处
期刊:Journal of The American Society of Nephrology
日期:2015-12-17
卷期号:27 (8): 2319-2330
被引量:91
标识
DOI:10.1681/asn.2015060634
摘要
Autosomal dominant polycystic kidney disease (ADPKD), one of the most common monogenetic disorders, is characterized by kidney failure caused by bilateral renal cyst growth. MicroRNAs (miRs) have been implicated in numerous diseases, but the role of these noncoding RNAs in ADPKD pathogenesis is still poorly defined. Here, we investigated the role of miR-21, an oncogenic miR, in kidney cyst growth. We found that transcriptional activation of miR-21 is a common feature of murine PKD. Furthermore, compared with renal tubules from kidney samples of normal controls, cysts in kidney samples from patients with ADPKD had increased levels of miR-21. cAMP signaling, a key pathogenic pathway in PKD, transactivated miR-21 promoter in kidney cells and promoted miR-21 expression in cystic kidneys of mice. Genetic deletion of miR-21 attenuated cyst burden, reduced kidney injury, and improved survival of an orthologous model of ADPKD. RNA sequencing analysis and additional in vivo assays showed that miR-21 inhibits apoptosis of cyst epithelial cells, likely through direct repression of its target gene programmed cell death 4 . Thus, miR-21 functions downstream of the cAMP pathway and promotes disease progression in experimental PKD. Our results suggest that inhibiting miR-21 is a potential new therapeutic approach to slow cyst growth in PKD.
科研通智能强力驱动
Strongly Powered by AbleSci AI